Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues

International Journal of STD and AIDS

Volumn 23, Issue 3, 2012, Pages 225-226

  Winston, A ^a   Moecklinghoff, C ^b   Hill, A ^c  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b University of Liverpool ^*

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANXIETY; ARTICLE; ATTENTION; ATTENTION DISTURBANCE; CLINICAL TRIAL (TOPIC); COGNITION; CONVULSION; DEPRESSION; DISEASE DURATION; DIZZINESS; DRUG DEPENDENCE; DRUG FATALITY; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPESTHESIA; INSOMNIA; ISCHIALGIA; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL DISEASE; MIGRAINE; MONOTHERAPY; NEUROLOGICAL COMPLICATION; OUTCOME ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; RATING SCALE; SIDE EFFECT; SLEEP DISORDER; SYNCOPE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; RITONAVIR; SULFONAMIDES;

EID: 84860914112     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011330     Document Type: Article

References (6)

1. Perez-Valero I, Bayon C, Cambon I, Gonzalez A, Arribas J. Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother 2011;66:1954-62
2. Yilmaz A, Izadkhashti A, Price R, et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1 infected adults. AIDS Res Hum Retroviruses 2009;25:1-5
3. Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS 2010;24:2365-74
4. Clumeck N, Rieger A, Banhegyi D, et al. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA,50 copies/mL at baseline. J Antimicrob Chemother 2011;66:1878-85
5. Cella DF, McCain NL, Peterman AH, Mo F, Wolen D. Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Qual Life Res 1996;5:450-63
6. UK Medical Research Council. A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy C PIVOT trial [online]. See http://www.controlled-trials.com/ISRCTN04857074 (last checked 13 May 2011).